安图生物
(603658)
| 流通市值：184.17亿 | | | 总市值：184.17亿 |
| 流通股本：5.71亿 | | | 总股本：5.71亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,057,927,123.1 | 992,202,191.51 | 4,226,413,277.24 | 3,127,156,171.6 |
| 营业收入 | 2,057,927,123.1 | 992,202,191.51 | 4,226,413,277.24 | 3,127,156,171.6 |
| 二、营业总成本 | 1,551,661,922.35 | 758,254,185.72 | 3,171,017,904.49 | 2,294,860,260.37 |
| 营业成本 | 674,033,046.31 | 330,992,970.52 | 1,452,300,743.96 | 1,099,754,181.57 |
| 税金及附加 | 32,626,051.47 | 15,916,555.61 | 62,570,065.66 | 43,820,703.41 |
| 销售费用 | 393,152,546.97 | 198,459,731.57 | 850,346,611.64 | 588,929,376.21 |
| 管理费用 | 132,340,943.14 | 70,708,301.98 | 241,291,919.7 | 163,164,328.7 |
| 研发费用 | 302,352,829.31 | 134,113,720.19 | 555,115,864.12 | 392,925,176.19 |
| 财务费用 | 17,156,505.15 | 8,062,905.85 | 9,392,699.41 | 6,266,494.29 |
| 其中:利息费用 | 5,993,474.69 | 2,725,390.3 | 13,958,489.76 | 11,878,575.69 |
| 其中:利息收入 | 8,700,228.11 | 3,584,259.67 | 7,079,028.42 | 4,280,372.11 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 28,802.44 | 1,201,247.29 | -3,495,613.67 | -2,656,044.42 |
| 加:投资收益 | 29,718,977.45 | 19,877,467.29 | 104,506,851.42 | 86,016,772.34 |
| 资产处置收益 | - | - | 637,786.38 | -3,315.41 |
| 资产减值损失(新) | 536,333.46 | 1,699,906.84 | -19,708,750.29 | -12,967,991.55 |
| 信用减值损失(新) | 172,123.76 | -2,867,259.07 | -8,950,967.28 | -4,405,590.05 |
| 其他收益 | 12,954,305.42 | 8,894,839.76 | 89,544,334.04 | 53,916,907.55 |
| 四、营业利润 | 549,675,743.28 | 262,754,207.9 | 1,217,929,013.35 | 952,196,649.69 |
| 加:营业外收入 | 1,899,116.31 | 1,055,929.03 | 20,022,116.23 | 18,307,958.53 |
| 减:营业外支出 | 5,421,474.93 | 1,823,377.28 | 15,184,737.02 | 11,330,294.22 |
| 五、利润总额 | 546,153,384.66 | 261,986,759.65 | 1,222,766,392.56 | 959,174,314 |
| 减:所得税费用 | 43,949,283.79 | 22,849,481.09 | 136,382,170.51 | 86,449,225.68 |
| 六、净利润 | 502,204,100.87 | 239,137,278.56 | 1,086,384,222.05 | 872,725,088.32 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 502,204,100.87 | 239,137,278.56 | 1,086,384,222.05 | 872,725,088.32 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 497,124,027.29 | 236,447,362.38 | 1,068,016,468.23 | 859,515,131.82 |
| 少数股东损益 | 5,080,073.58 | 2,689,916.18 | 18,367,753.82 | 13,209,956.5 |
| 扣除非经常损益后的净利润 | 493,172,493.18 | 232,433,248.15 | 998,383,780.15 | 815,477,646.46 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.87 | 0.41 | 1.87 | 1.5 |
| (二)稀释每股收益 | 0.87 | 0.41 | 1.87 | 1.5 |
| 八、其他综合收益 | -331,982.96 | -160,461.9 | -195,065.28 | -84,048.63 |
| 归属于母公司股东的其他综合收益 | -331,982.96 | -160,461.9 | -195,065.28 | -84,048.63 |
| 九、综合收益总额 | 501,872,117.91 | 238,976,816.66 | 1,086,189,156.77 | 872,641,039.69 |
| 归属于母公司股东的综合收益总额 | 496,792,044.33 | 236,286,900.48 | 1,067,821,402.95 | 859,431,083.19 |
| 归属于少数股东的综合收益总额 | 5,080,073.58 | 2,689,916.18 | 18,367,753.82 | 13,209,956.5 |
| 公告日期 | 2026-08-25 | 2026-04-23 | 2026-04-23 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |